Skip to main content

Table 1 Demographic, clinical and pathological features of study population

From: Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial

Demographic data Group P value
Control (n = 27) Intervention (n = 25)
Age (mean ± SD) 45.0 ± 8.36 41.0 ± 8.61 0.099
Weight (mean ± SD) 68.0 ± 9.52 70.0 ± 9.71 0.45
BMI (mean ± SD) 27.4 ± 4.37 27.7 ± 4.03 0.78
BSA (mean ± SD) 1.7 ± 0.1 1.7 ± 0.13 0.35
Positive family history n (%) 8 (29.6) 6 (24.0) 0.65
Regular Menstruation n (%) 20 (74.1) 21 (84.0) 0.38
Married n (%) 26 (96.0) 22 (88.0) 0.34
Parity (mean±SD) 2.8 ± 1.96 1.88 ± 1.36 0.069
Primary tumor size mm (mean±SD) 31.3 ± 19.54 41.2 ± 32.78 0.364
Initial T-stage n (%)
 TI 7 (25.9) 4 (16.0) 0.611
 T2 6 (22.2) 9 (36.0)
 T3 4 (14.8) 5 (20.0)
 T4 10 (37.0) 7 (28.0)
Tumor grade n (%)
 I 6 (22.2) 3 (12.0) 0.657
 II 13 (48.1) 13 (52.0)
 III 8 (29.6) 9 (36.0)
Node involvement n (%) 21 (77.7) 22 (88.0) 0.469
Hormonal status
 ER+ n (%) 21 (85.0) 23 (84.0) 1.00
 Extent of positivity (mean±SD) 74.3 ± 25.1 59.9 ± 33.9 0.104
 PR+ n (%) 19 (70.0) 14 (56.0) 0.28
 Extent of positivity (mean±SD) 48.7 ± 32.7 46.78 ± 32.7 0.869
HER2+ n (%) 10 (37.0) 8 (32.0) 0.43
ki67+a n (%) 15 (55.5) 19 (76.0) 0.122
ki67 (mean±SD) 34.8 ± 27.8 37.2 ± 23.7 0.742
Molecular Subtype
 HR+/HER2- 12 (44.4%) 9 (36%) 0.98
 HR+/HER2+ 11 (40.1%) 12 (48%)
 HR-/HER2+ 2 (7.4%) 2 (8%)
 TNBC 2 (7.4%) 2 (8%)
TILb n (%)
+ 13 (48.1) 10 (40.0) 0.554
- 14 (51.9) 15 (60.0)
  1. BMI Body mass index, BSA Body surface area, ER Estrogen receptor, PR Progesterone receptor, NACT neoadjuvant chemotherapy, TNBC Triple negative breast cancer, TIL Tumor-infiltrating lymphocytes
  2. aCut-off for ki67 positivity was 20%
  3. bCut-off for TIL was 10%